Calculate the Charlson Comorbidity Index with age adjustment from 19 comorbid conditions. Includes survival estimates, condition weights, and organ system breakdown.
The Charlson Comorbidity Index (CCI), developed by Mary Charlson and colleagues in 1987, is the most widely used and validated comorbidity scoring system in clinical medicine and research. It assigns weighted scores (1, 2, 3, or 6 points) to 19 comorbid conditions based on their impact on 1-year mortality risk, with the total score predicting patient outcomes.
The age-adjusted version adds 1 point per decade above age 50, recognizing that age itself is a significant predictor of mortality independent of disease burden. CCI scores are used in research to adjust for confounding by comorbidity, in clinical practice to summarize baseline disease burden, and in healthcare administration for risk stratification and case-mix adjustment.
This calculator provides the raw CCI score, age-adjusted CCI, estimated survival at 1, 5, and 10 years, interactive condition selection with weight visualization, and organ system categorization of selected comorbidities. Higher scores indicate greater comorbidity burden and lower predicted survival.
The Charlson Comorbidity Index is useful when you need one number that summarizes comorbidity burden for prognosis, risk adjustment, or cohort comparison. This calculator keeps the weighted conditions, age adjustment, and survival estimates together so the score can be interpreted without manually adding condition weights.
CCI = Σ (condition weights) Condition Weights: - 1 point: MI, CHF, PVD, CVA/TIA, dementia, COPD, connective tissue disease, PUD, mild liver disease, DM without complications - 2 points: DM with end-organ damage, hemiplegia, moderate-severe renal disease, non-metastatic solid tumor, leukemia, lymphoma - 3 points: Moderate-severe liver disease - 6 points: Metastatic solid tumor, AIDS Age Adjustment: +1 point per decade above age 50
Result: Raw CCI: 5 (CHF 1 + COPD 1 + DM with complications 2 + mild liver 1). Age-adjusted: 7 (5 + 2 for age 72).
A 72-year-old with four comorbidities has a raw CCI of 5 and age-adjusted CCI of 7. This puts them in the high comorbidity burden category with estimated 1-year survival of approximately 50% based on the original Charlson cohort.
Mary Charlson developed the CCI at Cornell University Medical Center using a prospective cohort of 559 internal medicine patients admitted in October 1984. The condition weights were derived from Cox proportional hazards regression on 1-year mortality. The index was validated on a separate cohort of 685 breast cancer patients, confirming its predictive ability across different populations. Since then, it has been cited over 40,000 times and adapted for ICD-9 and ICD-10 coding (Charlson-Deyo, Charlson-Romano adaptations).
While originally designed for mortality prediction, the CCI is now used for numerous applications: surgical risk review, cohort comparison, clinical trial stratification, healthcare cost prediction, quality reporting, and insurance risk adjustment. Its simplicity and widespread familiarity make it a common shorthand for comorbidity burden, though it does not replace disease-specific pathways.
Several updated versions exist: the Charlson-Deyo adaptation maps conditions to ICD codes for administrative data. The Quan update (2011) re-weighted conditions based on modern populations. The Combined Comorbidity Score integrates CCI with functional status. Despite these alternatives, the original Charlson weights remain the most commonly used in published literature.
Last updated:
This calculator sums the selected Charlson comorbidity weights, then adds the age-adjustment points shown on the page to produce the age-adjusted total. The score is displayed with the traditional burden framing so the user can review which conditions are driving the total rather than treating it as a black-box number.
The CCI is a comorbidity summary tool, not a stand-alone prognosis for an individual patient. It was derived for population-level outcome prediction and research adjustment, so bedside decisions still depend on the specific illness, severity, function, and current clinical course.
The CCI was developed in 1987 using a cohort of 559 medical patients at New York Hospital to predict 1-year mortality. Each condition's weight was derived from its relative risk for mortality. It has since been validated in hundreds of studies across diverse populations and clinical settings.
CCI uses 19 conditions with severity-based weights (1-6 points). Elixhauser uses 31 conditions without weighting, treating each as present/absent. Elixhauser captures more conditions (e.g., hypertension, obesity, depression) but requires more data. For administrative data, both are widely used; CCI is simpler while Elixhauser may have slightly better predictive performance.
The survival estimates are based on the original 1987 cohort and subsequent validation studies. Actual survival has improved significantly since then due to advances in treatment. Modern patients with the same CCI score likely have better outcomes than the original estimates suggest. The scores are most useful for relative risk comparison rather than absolute prediction.
The age-adjusted CCI is recommended when comparing patients of different ages or predicting outcomes in geriatric populations. The raw CCI is used when age is already controlled for in the analysis (e.g., in age-stratified studies). In clinical practice, the age-adjusted version provides a more complete picture of overall risk.
The CCI does not include hypertension, obesity, smoking, depression, or many other important conditions. This is because either they were not significant predictors in the original derivation cohort or they were too common to be discriminating. The Elixhauser index and the Combined Comorbidity Score capture some of these additional conditions.
CCI is primarily used as a confounder adjustment variable in observational studies. It appears in thousands of published studies as a standardized way to account for baseline health differences between treatment groups. It is also used for risk stratification in clinical trials and healthcare quality metrics.